On November 1, 2021 UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic diseases, reported that it will host a virtual "Spotlight Event" on Wednesday, November 10, 2021 at 11:00 a.m. Eastern Time (Press release, UroGen Pharma, NOV 1, 2021, View Source [SID1234594025]). The event will focus on UGN-102 (mitomycin) for intravesical solution for patients with low-grade non-muscle invasive bladder cancer (LG-NMIBC), and the Company’s earlier-stage clinical programs including UGN-301 and UGN-302.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
In addition to presentations from UroGen’s Chairman Arie Belldegrun, M.D. and members of the Company’s senior management team, the program will include a Key Opinion Leader panel discussion on the treatment of NMIBC.
Please register for the webinar on the Company’s website at www.urogen.com under the Events & Presentations section of the Investor Relations site (View Source).
Following the live audio webcast, a replay will be available on the Company’s website for approximately 30 days.
Third Quarter 2021 Financial Results
Additionally, the Company announced that it will report third quarter 2021 financial results on Monday, November 15, 2021, prior to the open of the market. The announcement will be followed by a live audio webcast and conference call at 10:00 AM Eastern Time.
The webcast will be available on the Investors section of the Company’s website at View Source Following the live audio webcast, a replay will be available on the Company’s website for 30 days.